Jumia Technologies’ shares hit the ground running-backward. A 9% dive on Friday, courtesy of a sell call that bit harder than a piranha in a bloodbath. The S&P 500 grinned up 0.5% while Jumia’s stock wept in monochrome.
Double Crossed
Nirgunan Tiruchelvam, the analyst with a sharper tongue than a switchblade, sliced his Jumia rating from buy to sell. His price target? $7.50-a number that now glows like a tombstone in the fog of $10.75. He’s not wrong to question the company’s net working capital. It’s a house built on sand, and the tide’s coming in fast.
Enterprise value-to-sales? Jumia trades at a premium to peers like a junkie haggling for a fix. The stock’s 153% rally since August reads like a fever dream. All the shine of a new dime, none of the heft.
Red Ink and Empty Pockets
CEO Francis Dufay waves a tariff truce like a holy water flask. Chinese vendors may be easier to handle than a drunk at a poker table, but Jumia’s bottom line still bleeds. Net losses aren’t habits-they’re addictions. And this stock? It’s a bridge with cracks you can’t see until you’re halfway across.
Dividend hunters don’t chase fireworks. They build bonfires with steady logs. Jumia’s chart looks like a suicide note written in candle wax. 🕯️
Read More
- Persona 5: The Phantom X – All Kiuchi’s Palace puzzle solutions
- How to Unlock Stellar Blade’s Secret Dev Room & Ocean String Outfit
- Leveraged ETFs: A Dance of Risk and Reward Between TQQQ and SSO
- 🚨 Pi Network ETF: Not Happening Yet, Folks! 🚨
- How to Do Sculptor Without a Future in KCD2 – Get 3 Sculptor’s Things
- Is Nebius a Buy?
- Quantum Bubble Bursts in 2026? Spoiler: Not AI – Market Skeptic’s Take
- Three Stocks for the Ordinary Dreamer: Navigating August’s Uneven Ground
- XRP Breaks Chains, SHIB Dreams Big, BTC Options Explode – A Weekend to Remember!
- PharmaTrace Scores 300K HBAR to Track Pills on the Blockchain-Because Counterfeit Drugs Needed a Tech Upgrade! 💊🚀
2025-10-18 01:15